ClinicalTrials.gg
Not yet recruitingNCT04357522Updated Apr 22, 2020

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

A Phase 3 interventional study of 15-Valent Pneumococcal Conjugate Vaccine and 13-Valent Pneumococcal Conjugate Vaccine in Pneumonia, Pneumococcal, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Not yet recruiting at 3 sites in China. Open to participants aged 6 Weeks to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-22.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,950
Allocation
Randomized
Ages
6 Weeks to 3 Months
Sex
All
01

Study summary

The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.

02

Conditions studied

  • Pneumonia, Pneumococcal
03

In context

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

This study's planned enrollment of 1,950 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.

Browse Pneumonia, Pneumococcal studies →

Lead sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is the lead sponsor of 22 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 3 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged above 2 months (minimum to 6 weeks), term (37-42 weeks gestation) and birth weight ≥2.5 kg.
  • The guardian understands the vaccination and research procedures, volunteers to participate in the research and sign the .
  • The guardian can follow the clinical research program, will be able to follow up until 3 years after booster immunization and have the ability to use thermometers, scale and fill in diary and contact cards as required.
  • There was no history of other in the past 14 days and no history of other inactivated vaccines in the seventh day.
  • Subaxillary body temperature \<=37.0 C.
  • Determine health based on medical history, physical examination, and researcher's judgment.

Exclusion criteria

Exclusion Criteria:

  • Have been vaccinated a listed or experimental pneumococcal vaccine.
  • History of invasive diseases caused by Streptococcus pneumoniae confirmed by bacterial culture in the past.
  • In the past, there was any history of vaccination or serious allergy to drugs. In the past, fever of over 39.5 C related to vaccination occurred in biological products for vaccination and prophylaxis.
  • History of convulsion, epilepsy, encephalopathy and psychiatry or family history.
  • Had abnormal labor (dystocia, device midwifery), history of asphyxia rescue and nerve organ damage.
  • History of pathological jaundice confirmed by diagnosis.
  • A history of thrombocytopenia or other coagulation disorders with definite diagnosis.
  • Human serum gamma globulin injection after birth.
  • There are known or suspected immunological abnormalities, including therapy (radiotherapy, chemotherapy, , antimetabolites, cytotoxic drugs), infection, etc.
  • Congenital malformations, severe malnutrition, developmental disorders, genetic defects (e.g. broad bean disease).
  • Severe chronic disease, infectious disease, active infection, liver disease, kidney disease, cardiovascular disease, malignant tumor.
  • Severe asthma.
  • Systemic rash, dermatophytes, skin pus or blister.
  • Participation in other drug clinical trials.
  • Anything that the researcher considers likely to affect the evaluation of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,950 participants (estimated)

Study arms

  • Experimental
    experimental group

    Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose

    Biological: 15-Valent Pneumococcal Conjugate Vaccine

  • Active comparator
    Positive control group

    Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose

    Biological: 13-Valent Pneumococcal Conjugate Vaccine

Interventions

  • Biological15-Valent Pneumococcal Conjugate Vaccine

    4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.

  • Biological13-valent pneumococcal vaccineStudies of 13-valent pneumococcal vaccine13-valent pneumococcal vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.

06

What researchers measure

Primary outcomes

  1. Immunogenicity study endpoint

    Percentage of participants with seroresponse to each vaccination

    Time frame: 30 day after each vaccination

  2. Safety study endpoint

    Occurrence of adverse events during a 30 day follow-up period after each vaccination

    Time frame: 30 day after each vaccination

07

Study locations

3 sites
  • Daming Center for Disease Control and Prevention
    Daming, Hebei 056900, China
  • Laishui Center for Disease Control and Prevention
    Laishui, Hebei 074199, China
  • Zhengding Center for Disease Control and Prevention
    Zhengding, Hebei 050800, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2020; primary completion for Mar 2026, 68 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2020
First posted
Apr 22, 2020
StartEst.
Jul 2020
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Apr 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04357522
Responsible party
Sponsor
First posted
Apr 22, 2020
Start date
Jul 2020 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Apr 22, 2020

Study contacts

Du Lin, Master
study chair · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion